Literature DB >> 3113968

Normal pathways for glucuronidation, sulphation and oxidation of paracetamol in Gilbert's syndrome.

D Ullrich, A Sieg, R Blume, K W Bock, W Schröter, J Bircher.   

Abstract

A group of eleven subjects with Gilbert's syndrome was characterized by conventional tests and determination of bilirubin and its conjugates in plasma by alkaline methanolysis and thin layer chromatography. After a 1 g dose of paracetamol h.s. the drug and its metabolites were measured by high performance liquid chromatography (HPLC) in the overnight 8-h urine sample. The amounts of paracetamol and of its metabolites recovered in urine were almost identical with those found in the control group (n = 10). The glucuronide:paracetamol ratio, which is considered to be an index of glucuronidation, was not correlated with the fraction of bilirubin present in plasma as glucuronides. These data do not suggest that in subjects with Gilbert's syndrome therapeutic doses of paracetamol are associated with an increased risk for hepatic or systemic toxicity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3113968     DOI: 10.1111/j.1365-2362.1987.tb01242.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  10 in total

Review 1.  Glucuronidation in humans. Pharmacogenetic and developmental aspects.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

2.  N-acetylation and debrisoquine hydroxylation polymorphisms in patients with Gilbert's syndrome.

Authors:  W Siegmund; J D Fengler; G Franke; M Zschiesche; O Eike; E Eike; P Meisel; R Wulkow
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

3.  PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses.

Authors:  Liudmila L Mazaleuskaya; Katrin Sangkuhl; Caroline F Thorn; Garret A FitzGerald; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-08       Impact factor: 2.089

4.  UGT1A6 and UGT2B15 polymorphisms and acetaminophen conjugation in response to a randomized, controlled diet of select fruits and vegetables.

Authors:  Sandi L Navarro; Yu Chen; Lin Li; Shuying S Li; Jyh-Lurn Chang; Yvonne Schwarz; Irena B King; John D Potter; Jeannette Bigler; Johanna W Lampe
Journal:  Drug Metab Dispos       Date:  2011-06-10       Impact factor: 3.922

5.  Time course of acetaminophen-protein adducts and acetaminophen metabolites in circulation of overdose patients and in HepaRG cells.

Authors:  Yuchao Xie; Mitchell R McGill; Sarah F Cook; Matthew R Sharpe; Robert D Winefield; Diana G Wilkins; Douglas E Rollins; Hartmut Jaeschke
Journal:  Xenobiotica       Date:  2015-04-14       Impact factor: 1.908

6.  Heterogeneity of paracetamol metabolism in Gilbert's syndrome.

Authors:  A Esteban; M Pérez-Mateo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Jan-Mar       Impact factor: 2.441

Review 7.  Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors.

Authors:  H K Kroemer; U Klotz
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

Review 8.  Metabolism and disposition of acetaminophen: recent advances in relation to hepatotoxicity and diagnosis.

Authors:  Mitchell R McGill; Hartmut Jaeschke
Journal:  Pharm Res       Date:  2013-03-06       Impact factor: 4.200

Review 9.  Genetic and environmental factors associated with variation of human xenobiotic glucuronidation and sulfation.

Authors:  B Burchell; M W Coughtrie
Journal:  Environ Health Perspect       Date:  1997-06       Impact factor: 9.031

Review 10.  Are some people at increased risk of paracetamol-induced liver injury? A critical review of the literature.

Authors:  Thomas M Caparrotta; Daniel J Antoine; James W Dear
Journal:  Eur J Clin Pharmacol       Date:  2017-10-24       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.